Biogen abandons tau antibody for Alzheimer’s after phase 2 missBiogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – Share XBiogen abandons tau antibody for Alzheimer’s after phase 2 misshttps://pharmaphorum.com/news/biogen-abandons-tau-antibody-for-alzheimers-after-phase-2-miss/
Consumer group seeks resignation of top FDA staffers over Aduhelm okayWith the first patient set to receive Biogen’s new Alzheimer’s drug Aduhelm in Rhode Island today, US consumer Share XConsumer group seeks resignation of top FDA staffers over Aduhelm okayhttps://pharmaphorum.com/news/consumer-group-seeks-resignation-of-top-fda-staffers-over-aduhelm-okay/
And then there were three: another FDA adcomm member quits over AduhelmThe fallout over the FDA’s decision to approved Biogen’s Alzheimer’s therapy Aduhelm continues to be felt, with a Share XAnd then there were three: another FDA adcomm member quits over Aduhelmhttps://pharmaphorum.com/news/and-then-there-were-three-another-fda-adcomm-member-quits-over-aduhelm/
Double resignation over Aduhelm approval depletes FDA’s CNS adcommTwo members of an FDA advisory committee have now resigned in protest over Monday’s approval of Biogen’s Alzheimer’s Share XDouble resignation over Aduhelm approval depletes FDA’s CNS adcommhttps://pharmaphorum.com/news/double-resignation-over-aduhelm-approval-depletes-fdas-cns-adcomm/
Aduhelm approval could signal new era for CNS drugs; analystsThe unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the Share XAduhelm approval could signal new era for CNS drugs; analystshttps://pharmaphorum.com/news/aduhelm-approval-could-signal-new-era-for-cns-drugs-analysts/
Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinicBayer subsidiary BlueRock Therapeutics has dosed the first Parkinson’s disease patient in a phase 1 trial of its Share XBayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinichttps://pharmaphorum.com/news/bayers-two-pronged-cell-gene-therapy-assault-on-parkinsons-enters-clinic/
FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tagThe FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” Share XFDA slammed over Aduhelm OK as Biogen takes heat for $56k price taghttps://pharmaphorum.com/news/fda-slammed-over-aduhelm-ok-as-biogen-takes-heat-for-56k-price-tag/
Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumabBiogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab Share XJubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumabhttps://pharmaphorum.com/news/jubilation-at-biogen-as-fda-says-yes-to-aducanumab/
Akili raises $110m to build its digital therapeutics pipelineDigital health player Akili has raised $110 million fourth-round funding, backed by a number of pharma groups, as Share XAkili raises $110m to build its digital therapeutics pipelinehttps://pharmaphorum.com/news/akili-raises-110m-to-build-its-digital-therapeutics-pipeline/
